Table 1 Site characteristics
Site ID | Allocated Study Arm | Site Location | Funding Type | Number of patients seen per 3-month period | Number of departments included | Treatment modality departments included | Tumour Streams included | Number of streams included | FTE Psycho-social staff | Screening History in past 12 months |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Core | Major city | Public | ≥100 | 3 | Med Oncology Rad Oncology Haematology | All | ≥3 | 0.8 | Yes |
2 | Enhanced | Inner regional | Public | < 100 | 4 | Med Oncology Rad Oncology Haematology Surgical | All | ≥3 | 0.6 | No |
3 | Core | Inner regional | Public | < 100 | 1 | Med Oncology | All | ≥3 | 0.6 | No |
4 | Enhanced | Major city | Public | ≥100 | 2 | Med Oncology Surgical | Gastro-intestinal | 1 | 2.4 | No |
5 | Enhanced | Inner regional | Public | < 100 | 3 | Med Oncology Rad Oncology Haematology | All | ≥3 | 1 | Yes |
6 | Enhanced | Major city | Public | ≥100 | 2 | Med oncology Haematology | All | ≥3 | 7.9 | No |
7 | Enhanced | Major city | Public | ≥100 | 1 | Surgical | Upper GI | 1 | 2.4 | Yes |
8 | Enhanced | Major city | Public | < 100 | 3 | Med Oncology Rad Oncology Haematology | All | ≥3 | 5 | Yes |
9 | Enhanced | Major city | Public | ≥100 | 1 | Haematology | Lymphoma, acute leukemia, multiple myeloma | ≥3 | 2.4 | No |
10 | Enhanced | Major city | Public | ≥100 | 3 | Med Oncology Rad Oncology Surgical | Head & Neck | 1 | 4 | No |
11 | Core | Major city | Public and Private | ≥100 | 1 | Med Oncology | Sarcoma, Gynae | 2 | 6.9 | Yes |
12 | Core | Major city | Private | ≥100 | 1 | Med Oncology | All | ≥3 | 0.9 | No |